ArticleFrontiers in psychiatry2026
Peripheral blood CADM1 expression and multi-gene signatures in depressive disorders: a pilot case-control study from the United Arab Emirates.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depressive disorders are a leading cause of global disability, yet gene expression studies in Middle Eastern populations remain scarce. This study investigated peripheral blood expression of seven candidate genes, previously identified in animal models and early-onset depression, in adults with and without depressive disorders in United Arab Emirates (UAE). Methods: In a case-control design, 49 adults with depressive disorders (ICD-10 major depressive disorder, dysthymia, or adjustment disorder with depressed features) and 49 non-depressed controls were assessed with the Beck Depression Inventory-II and Patient Health Questionnaire-9. Peripheral blood expression of ADCY3, DGKA, FAM46A, CADM1, KIAA1539, MARCKS, and RAPH1 was measured by quantitative real-time PCR, normalised to GAPDH. Analyses included Mann-Whitney U tests, principal component analysis, fold-change estimation, pre-specified receiver operating characteristic analysis, and severity-restricted, age-balanced, and RNA-quality sensitivity analyses. Results: CADM1 showed modest upregulation in the depressive disorder group (1.30-fold; Mann-Whitney p = 0.049, uncorrected) that did not survive multiple testing correction (Benjamini-Hochberg p = 0.178). Principal component analysis revealed an unadjusted PC2 difference (p = 0.006), driven by CADM1 and RAPH1, that attenuated after age adjustment (MANCOVA p = 0.156). CADM1 correlated negatively with depression severity (BDI-II ρ = -0.280, p = 0.005), and the signal strengthened monotonically across severity strata (moderate-severe BDI-II ≥ 20, p = 0.029; severe BDI-II ≥ 29, p = 0.014), arguing against diagnostic heterogeneity as the primary driver. However, propensity score matching on age abolished the CADM1 effect (p = 0.965). Exploratory subgroup analyses suggested sex-specific patterns (CADM1 in males, p = 0.039; KIAA1539 in females, p = 0.010). The CADM1 area under the receiver operating characteristic curve was 0.616, indicating no diagnostic utility. Conclusions: This pilot provides the first peripheral blood gene expression data for depression in a UAE population. Given the small sample, the 13-year mean age difference between groups, and unmeasured confounders, CADM1 is best framed as a hypothesis-generating candidate only; the signal was unstable after age balancing and the discrimination performance (AUC = 0.616) is below any clinically useful threshold. Validation in larger, strictly age-matched studies is required before any clinical interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.